Study on regulatory mechanism of liver regeneration

本研究旨在开发治疗重型肝炎的新模式，这是众所周知的疾病显示非常高的模式。也就是说，为了提高在这种情况下的存活率，毫无疑问，在携带大量肝坏死的肝脏中，促进肝再生是绝对必要的。因此，有关肝再生的调控机制及其在重型肝炎治疗中的应用的研究已经开展。在未来的几年内，我们可以利用单克隆抗溴脱氧尿苷抗体建立新的肝再生分析方法。在过去的研究中，我们清楚地表明，胰高血糖素和胰岛素同时输注不仅促进部分肝切除大鼠肝脏的肝再生，而且还促进严重损伤的肝脏。然而，我们可以补充新的证据，即人表皮生长因子是由大肠杆菌产生的。大肠杆菌与其他两种胰腺激素合用，对肝再生的促进作用更强。这一结果可能是发展重型肝炎新的治疗模式的关键。此外，对包括暴发性肝炎在内的各种肝病患者血清中人表皮生长因子含量的测定也有重要意义。我们还成功地建立了抗hEGF的酶免疫分析系统。

This study has been aimed to develop new modality in therapy of fulminant hepatitis which is well-known to be disease showing very high modality. That is, in order to improve the survival rate in this condition it is no doubt that promotion of liver regeneration will be absolutely necessary in the liver carrying massive liver necrosis. Therefore, studies concerning regulatory mechanism of liver regeneration and its application to the therapy of fulminant hepatitis has been performed. During due years, we could developed new method for analysis of liver regeneration using monoclonal anti-bromodeoxy uridine antibody. In the past study, we made clear that simultaneous infusion of glucagon and insulin promoted liver regeneration not only in partial hepatectomized rat liver, but also in the severely damaged liver. However, we could add the new evidence that human epidermal growth factor which was produced by E. Coli promoted the liver regeneration much more in its concomitant use with other two pancreatic hormones. This result might be key for development of new therapeutic modality of fulminant hepatitis. Furthermore, it is also important to measure the content of human epidermal growth factor in the sera among the cases carrying miscellaneous liver diseases including fulminant hepatits. We also succeeded to this assay system using enzyme immunoassay usin anti hEGF.